Suppr超能文献

含聚己内酯和透明质酸的可注射填充凝胶的制备与表征

Preparation and Characterization of Injectable Augmentation Gels Containing Polycaprolactone and Hyaluronic Acid.

作者信息

Turkmen Meryem Erken, Ghaffarlou Mohammadreza, Kilic Busra, Karaaslan Cagatay, Aydin Halil Murat

机构信息

Bioengineering Division, Institute of Science, Hacettepe University, Ankara, Turkey.

Molecular Biology Section, Department of Biology, Faculty of Science, Hacettepe University, Ankara, Turkey.

出版信息

J Cosmet Dermatol. 2025 Feb;24(2):e16730. doi: 10.1111/jocd.16730. Epub 2024 Dec 16.

Abstract

BACKGROUND

Injectable augmentation gels are widely used in the treatment of soft tissue. The composition of these gels has to be continuously improved due to the limitations of the currently available formulations.

AIMS

This study focuses on the development of an innovative injectable gel designed to address current trends and specific needs within the field.

METHODS

The current study utilized a safer hyaluronic acid (HA) gel carrier, created with a less toxic cross-linker, in combination with polycaprolactone (PCL) microspheres at various concentrations. PCL microspheres were prepared using an emulsification-solvent evaporation technique. Six different gel formulations were developed using PCL microspheres and biphasic HA gel structures.

RESULTS

The produced microspheres had non-agglomerated, smooth surfaces with an average particle size of approximately 45 ± 0.14 μm. The rheological results of the PCL-HA6 such as storage modulus (G', Pa), loss modulus (G", Pa), complex viscosity (η*), and phase angle (°) at 1 Hz frequency were measured as 553.97 ± 32.48, 368.4 ± 12.24, 105.9 ± 5.27, and 33.65 ± 0.92, respectively, and the injection force was measured as 9.64 ± 1.46. In vitro tests revealed that the PCL-HA6 group showed the highest cell viability compared to the other groups and provided a relative increase in collagen production over time, as demonstrated by the relevant gene expression.

CONCLUSIONS

The developed PCL/HA gel exhibited biocompatibility and non-toxicity, making it a safe option for soft tissue augmentation. It demonstrated potential for medical applications and exhibited favorable rheological characteristics and injectability.

摘要

背景

可注射填充凝胶广泛应用于软组织治疗。由于现有配方存在局限性,这些凝胶的成分必须不断改进。

目的

本研究聚焦于开发一种创新型可注射凝胶,以满足该领域当前的趋势和特定需求。

方法

本研究采用了一种更安全的透明质酸(HA)凝胶载体,该载体由毒性较小的交联剂制成,并与不同浓度的聚己内酯(PCL)微球相结合。PCL微球采用乳化溶剂蒸发技术制备。使用PCL微球和双相HA凝胶结构开发了六种不同的凝胶配方。

结果

所制备的微球表面无团聚、光滑,平均粒径约为45±0.14μm。PCL-HA6在1Hz频率下的流变学结果,如储能模量(G',Pa)、损耗模量(G'',Pa)、复数粘度(η*)和相角(°),分别测定为553.97±32.48、368.4±12.24、105.9±5.27和33.65±0.92,注射力测定为9.64±1.46。体外试验表明,与其他组相比,PCL-HA6组显示出最高的细胞活力,并且随着时间的推移胶原蛋白产量相对增加,相关基因表达证明了这一点。

结论

所开发的PCL/HA凝胶具有生物相容性和无毒性,使其成为软组织填充的安全选择。它展示了医疗应用潜力,并具有良好的流变学特性和可注射性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a43f/11837236/0ce28b54e619/JOCD-24-e16730-g003.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验